DM Healthcare Investment

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

August 25, 2022

EDEN PRAIRIE, Minn., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology. This new patent further expands the Company's extensive patent portfolio covering the bioengineering of transplantable organs.

U.S. Patent Number 11,414,644 is entitled "Methods of Recellularizing a Tissue or Organ for Improved Transplantability." This patent covers the revascularization of decellularized organs and tissues that encompasses all types of organs including liver, lung, kidney, and heart.

"Organ transplantation is one of the largest unmet medical needs facing the world today," says Miromatrix CEO Jeff Ross, Ph.D. "This important patent demonstrates our ability to revascularize decellularized organs and furthers our commitment to bioengineering completely functional, transplantable organs to solve this major health crisis."

Miromatrix's perfusion decellularization and recellularization technology platform includes 119 issued and 34 pending patent applications, with protection in the United States and major markets worldwide.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.